Latest News about BNTX
Recent news which mentions BNTX
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
August 26, 2022
From Benzinga
From Benzinga
Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization
August 24, 2022
From MarketWatch
Here's Why This Dominant Income Stock Is a Buy
August 24, 2022
From Motley Fool
From MarketWatch
Pfizer and BioNTech say data shows COVID vaccine has more than 70% efficacy in small children, and cases now rising in just 7 states
August 23, 2022
From MarketWatch
Pfizer/BioNTech's COVID-19 Vaccine Updated Data Shows Around 76% Efficacy In Toddlers
August 23, 2022
From Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 22, 2022
From Benzinga
Boosters Are Coming For Dangerous Omicron COVID-19 Variant. Here's Who May Be Rolling Them Out
August 22, 2022
From Benzinga
From Benzinga
Jill Biden leaves isolation after twice testing negative and Novavax vaccine allowed for teens
August 22, 2022
From MarketWatch
From Benzinga
Canada OKs Pfizer COVID-19 Booster For Kids Aged 5-11 Years
August 22, 2022
From Benzinga
The Rise and Fall of Novavax
August 21, 2022
From Motley Fool
What will insurance coverage of COVID-19 vaccines and treatments look like? The Biden administration is trying to figure that out
August 19, 2022
From MarketWatch
Large-scale study finds COVID patients at higher risk of brain fog and psychosis after two years compared with other respiratory illnesses
August 18, 2022
From MarketWatch
From Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
August 17, 2022
From InvestorPlace
A Look Into Healthcare Sector Value Stocks
August 15, 2022
From Benzinga
U.K. regulator is first to authorize Moderna’s bivalent COVID booster for adults aged 18 and older
August 15, 2022
From MarketWatch
1 Hot Growth Stock to Buy, and 1 to Avoid (For Now)
August 15, 2022
From Motley Fool
Landmark Drug Pricing Reform Bill Passes Congress House
August 15, 2022
From Benzinga
From Benzinga
From Motley Fool
From Benzinga
Goldman Sachs has lowered its price target for BioNTech (BNTX) to $200. BNTX is trading at $157.86
August 09, 2022
Tickers
BNTX
From Best Stocks
From MarketWatch
7 Blue-Chip Stocks That Will Survive 2022
August 09, 2022
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.